172 related articles for article (PubMed ID: 33361353)
1. Revisiting heart failure assessment based on objective measures in NYHA functional classes I and II.
Blacher M; Zimerman A; Engster PHB; Grespan E; Polanczyk CA; Rover MM; Neto JAF; Danzmann LC; Bertoldi EG; Simões MV; Beck-da-Silva L; Biolo A; Rohde LE
Heart; 2021 Sep; 107(18):1487-1492. PubMed ID: 33361353
[TBL] [Abstract][Full Text] [Related]
2. Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial.
McKelvie RS; Komajda M; McMurray J; Zile M; Ptaszynska A; Donovan M; Carson P; Massie BM;
J Card Fail; 2010 Feb; 16(2):128-34. PubMed ID: 20142024
[TBL] [Abstract][Full Text] [Related]
3. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction.
Rørth R; Jhund PS; Yilmaz MB; Kristensen SL; Welsh P; Desai AS; Køber L; Prescott MF; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV
Circ Heart Fail; 2020 Feb; 13(2):e006541. PubMed ID: 32065760
[TBL] [Abstract][Full Text] [Related]
4. Effects of ivabradine therapy on heart failure biomarkers.
Ordu S; Yildiz BS; Alihanoglu YI; Ozsoy A; Tosun M; Evrengul H; Kaftan HA; Ozhan H
Cardiol J; 2015; 22(5):501-9. PubMed ID: 25733317
[TBL] [Abstract][Full Text] [Related]
5. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.
von Haehling S; Jankowska EA; Morgenthaler NG; Vassanelli C; Zanolla L; Rozentryt P; Filippatos GS; Doehner W; Koehler F; Papassotiriou J; Kremastinos DT; Banasiak W; Struck J; Ponikowski P; Bergmann A; Anker SD
J Am Coll Cardiol; 2007 Nov; 50(20):1973-80. PubMed ID: 17996563
[TBL] [Abstract][Full Text] [Related]
6. Associations Between New York Heart Association Classification, Objective Measures, and Long-term Prognosis in Mild Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial.
Rohde LE; Zimerman A; Vaduganathan M; Claggett BL; Packer M; Desai AS; Zile M; Rouleau J; Swedberg K; Lefkowitz M; Shi V; McMurray JJV; Solomon SD
JAMA Cardiol; 2023 Feb; 8(2):150-158. PubMed ID: 36477809
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of sST2 and NT-proBNP at admission in heart failure with preserved, mid-ranged and reduced ejection fraction.
Huang A; Qi X; Hou W; Qi Y; Zhao N; Liu K
Acta Cardiol; 2018 Feb; 73(1):41-48. PubMed ID: 28944719
[TBL] [Abstract][Full Text] [Related]
8. Rational and design of a randomized, double-blind, multicenter trial to evaluate the safety and tolerability of furosemide withdrawal in stable chronic outpatients with heart failure: The ReBIC-1 trial.
da Rosa PR; Rohde LE; Doebber M; Ribeiro ALP; Prado DP; Bertoldi EG; Figueiredo Neto JA; Kohler I; Beck-da-Silva L; Danzmann LC; Moura LZ; Rover M; Simões MV; Sant'Anna RT; Biolo A
Am Heart J; 2017 Dec; 194():125-131. PubMed ID: 29223430
[TBL] [Abstract][Full Text] [Related]
9. Associations With and Prognostic and Discriminatory Role of N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Versus Mid-range Versus Reduced Ejection Fraction.
Savarese G; Orsini N; Hage C; Dahlström U; Vedin O; Rosano GMC; Lund LH
J Card Fail; 2018 Jun; 24(6):365-374. PubMed ID: 29597053
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of NT-proBNP added to clinical parameters to predict two-year prognosis of chronic heart failure patients with mid-range and reduced ejection fraction - A report from FAR NHL prospective registry.
Spinar J; Spinarova L; Malek F; Ludka O; Krejci J; Ostadal P; Vondrakova D; Labr K; Spinarova M; Pavkova Goldbergova M; Benesova K; Jarkovsky J; Parenica J
PLoS One; 2019; 14(3):e0214363. PubMed ID: 30913251
[TBL] [Abstract][Full Text] [Related]
11. Maximum longitudinal relaxation velocity of the left ventricle: its clinical value and relationship with NT-proBNP plasma levels in heart failure.
Taléns-Visconti R; Rivera M; Climent V; Valero R; Martínez-Dolz L; Sancho-Tello MJ; Cortés R; Miro V; Sevilla B; Perez-Bosca JL; Bertomeu V; Salvador A; Jordan A; Marin F; Sogorb F
Echocardiography; 2006 Apr; 23(4):295-302. PubMed ID: 16640706
[TBL] [Abstract][Full Text] [Related]
12. Clinical Implications of the New York Heart Association Classification.
Caraballo C; Desai NR; Mulder H; Alhanti B; Wilson FP; Fiuzat M; Felker GM; Piña IL; O'Connor CM; Lindenfeld J; Januzzi JL; Cohen LS; Ahmad T
J Am Heart Assoc; 2019 Dec; 8(23):e014240. PubMed ID: 31771438
[TBL] [Abstract][Full Text] [Related]
13. N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study.
Ezekowitz JA; O'Connor CM; Troughton RW; Alemayehu WG; Westerhout CM; Voors AA; Butler J; Lam CSP; Ponikowski P; Emdin M; Patel MJ; Pieske B; Roessig L; Hernandez AF; Armstrong PW
JACC Heart Fail; 2020 Nov; 8(11):931-939. PubMed ID: 33039447
[TBL] [Abstract][Full Text] [Related]
14. N-terminal pro-B-type natriuretic peptide in chronic heart failure: The impact of sex across the ejection fraction spectrum.
Faxén UL; Lund LH; Orsini N; Strömberg A; Andersson DC; Linde C; Dahlström U; Savarese G
Int J Cardiol; 2019 Jul; 287():66-72. PubMed ID: 31005415
[TBL] [Abstract][Full Text] [Related]
15. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease.
Neuhold S; Huelsmann M; Strunk G; Stoiser B; Struck J; Morgenthaler NG; Bergmann A; Moertl D; Berger R; Pacher R
J Am Coll Cardiol; 2008 Jul; 52(4):266-72. PubMed ID: 18634981
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation.
Kristensen SL; Jhund PS; Mogensen UM; Rørth R; Abraham WT; Desai A; Dickstein K; Rouleau JL; Zile MR; Swedberg K; Packer M; Solomon SD; Køber L; McMurray JJV;
Circ Heart Fail; 2017 Oct; 10(10):. PubMed ID: 29018174
[TBL] [Abstract][Full Text] [Related]
17. N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status.
Kristensen SL; Mogensen UM; Jhund PS; Rørth R; Anand IS; Carson PE; Desai AS; Pitt B; Pfeffer MA; Solomon SD; Zile MR; Køber L; McMurray JJV
Circ Heart Fail; 2019 Mar; 12(3):e005766. PubMed ID: 30871349
[TBL] [Abstract][Full Text] [Related]
18. Vitamin D deficiency in patients with diastolic dysfunction or heart failure with preserved ejection fraction.
Nolte K; Herrmann-Lingen C; Platschek L; Holzendorf V; Pilz S; Tomaschitz A; Düngen HD; Angermann CE; Hasenfuß G; Pieske B; Wachter R; Edelmann F
ESC Heart Fail; 2019 Apr; 6(2):262-270. PubMed ID: 30784226
[TBL] [Abstract][Full Text] [Related]
19. Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial.
Nassif ME; Windsor SL; Tang F; Khariton Y; Husain M; Inzucchi SE; McGuire DK; Pitt B; Scirica BM; Austin B; Drazner MH; Fong MW; Givertz MM; Gordon RA; Jermyn R; Katz SD; Lamba S; Lanfear DE; LaRue SJ; Lindenfeld J; Malone M; Margulies K; Mentz RJ; Mutharasan RK; Pursley M; Umpierrez G; Kosiborod M
Circulation; 2019 Oct; 140(18):1463-1476. PubMed ID: 31524498
[TBL] [Abstract][Full Text] [Related]
20. Old markers, new approach to assessment of risk in heart failure.
Kodziszewska K; Leszek P; Korewicki J; Piotrowski W
Kardiol Pol; 2015; 73(6):387-95. PubMed ID: 25563469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]